EMEA-001613-PIP01-14-M04 - paediatric investigation plan

tezepelumab
PIPHuman

Key facts

Active Substance
tezepelumab
Therapeutic area
Pneumology-allergology
Decision number
P/0012/2020
PIP number
EMEA-001613-PIP01-14-M04
Pharmaceutical form(s)
Solution for injection
Condition(s) / indication(s)
Treatment of asthma
Route(s) of administration
Subcutaneous use
Contact for public enquiries

AstraZeneca AB (Sweden)

Tel.  +46 855326000
E-mail: paediatrics@astrazeneca.com

Decision type
PM: decision on the application for modification of an agreed PIP
Decision date

Decision

Share this page